Xenon stock plunges as B.C. drug developer pauses enrolment in depression study
Xenon Pharmaceuticals (XENE) halted enrollment in a depression study due to adverse events, causing its stock to drop 29% to $40.60. The company submitted a new drug application for its epilepsy treatment, azetukalner, which showed promising results in reducing seizures. Analysts cut price targets but remain optimistic about the epilepsy drug's potential.
How this was made
The 30-second read
Why it matters
The trial pause caused a sharp sell‑off, reflecting heightened risk perception among investors.
Market read
The news directly affected XENE's share price and may influence broader biotech risk sentiment.
What to watch
The epilepsy NDA remains on track; the pause may be a temporary safety review.
Background
Xenon Pharmaceuticals (XENE) is a Nasdaq‑listed biotech developing azetukalner for epilepsy and depression.
Ticker impact
Xenon paused enrolment in its late‑stage depression trial, triggering a 29% intraday drop.
Expect continued downside pressure; potential further 5‑10% decline if data not clarified.
A 29% sell‑off on news of adverse events in a pivotal trial indicates strong negative market reaction.
Market effects
May dampen sentiment for biotech companies with psychiatric pipelines.
Negative impact on Canadian biotech sector indices.
Limited to investors focused on biotech and clinical‑trial risk.
Counterpoint
If the epilepsy indication remains strong, the stock could rebound on the upside.
Key entities
- CEOIan Mortimer
Provided commentary on the trial pause.
- Chief Medical OfficerChris Kenney
Described adverse events observed in the depression trial.
